Group items matching

in title, tags, annotations or url

Health Education England (HEE) has invited community pharmacy contractors to a meeting to discuss training of pharmacists to become Independent Prescribers (IP). Earlier, HEE together with NHS England and NHS Improvement has supported a first phase of IP training for community pharmacists from January to March 2022, and is now working to secure a further rounded of funded training from Autumn 2022. The upcoming virtual meeting is aimed to help inform future independent prescribertraining offers by ensuring it is aligned with the needs of the pharmacy workforce.

To curb the supply issue of HRT medicine, the government has taken a further action by issuing SSPs for Oestrogel, Ovestin cream, Lenzetto transdermal spray and Sandrena gel sachets - with appropriate alternatives. The move aims to allow community pharmacists to supply specified alternatives to the prescribed HRT products without needing to seek authorisation from the clinician who has prescribed the medicine. The regulator said that the availability of Premique Low Dose has impoved 'thanks to SSPs issued on 29 April to restrict dispensing for Oestrogel, Ovestin and Premique Low Dose to three months' supply'. "Since these measures were implemented, further deliveries of all three products have been made, with Premique Low Dose returning to good availability this week. The manufacturers of Oestrogel and Ovestin, as well as suppliers of alternative HRT products, are taking action to increase UK supply." It added, "SSPs restricting prescriptions to a maximum of three months' supply will also be issued for substitute products, as a precautionary measure to ensure the supply of those substitutes is maintained."

The Royal Pharmaceutical Society (RPS) has backed a new framework from NHS England to reduce inappropriate prescribing of addiction-causing medicines. It believes that the new framework is a positive step towards improving patient care by supporting medicine reviews and shared decision making to help people reduce their use of medicines that are no longer providing much clinical benefit. The society has also welcomed investment in innovative approaches to supporting patients and urged all pharmacists to refer people to such schemes. Director for England at RPS, James Davies said: "Pharmacists are well-placed to help reduce inappropriate prescribing of high strength painkillers such as opioids and other addictive medicines. "Pharmacy teams can also often spot repeat purchases of over the counter medicines by patients so are well placed to intervene and give advice on the management of chronic pain. Whilst opioids can play an important part in helping people with chronic pain there has long been a need for alternative approaches that are safer and more effective for patients.

The International Pharmaceutical Federation (FIP) has offered a new resource to help countries self-assess readiness of their regulations to enable pharmacist-delivered vaccination services and, where needed, to implement such regulations. Developed by FIP's Regulators Advisory Group, it covers broad pharmacist-led roles related to vaccination from supply chain management to administration and prescribing. "This new resource from FIP is based on the experiences of professional regulators in countries where pharmacy-led vaccination has been successfully introduced and regulated. With it, we aim to support regulators, policymakers and national organisations in developing strategies or enabling regulatory frameworks in countries where the pharmacy workforce has a limited role in vaccination strategies so that it can contribute further to the global imperative of improving immunisation coverage," said Brett Simmonds, group chair. The "Pharmacy-led vaccination services: Regulatory self-assessment and implementation tool" aims to help identify strengths and areas for improvement in order to inform vaccination policy and planning efforts.

The large majority of adults in the England knew that flu jabs are available in many pharmacies, just over half were aware of the GP Community Pharmacist Consultation Service or the New Medicine Service, according to a new survey by the National Pharmacy Association (NPA). The new survey revealed the need to raise the public awareness of key NHS services such as the New Medicine Service. According to the survey, 56 per cent of those asked believed that pharmacies in England offer NHS consultations for people newly prescribed a medicine for a long-term condition. While 48 per cent believed that many pharmacies in England offer blood pressure monitoring (NHS or private). 51 per cent believed it to be true that GPs can formally refer patients for same-day clinical advice from their local pharmacist about minor ailments.

The Royal Pharmaceutical Society (RPS) Wales and the Association of the British Pharmaceutical Industry (ABPI) co-hosted a drop-in session to inform members of the Senedd (MSs) about the action taken by pharmacists to make medicines use more sustainable. At a 'drop-in' session the ABPI, RPS members and staff had the opportunity to speak to a number of MSs from all political parties. "With medicines accounting for around 25 per cent of the NHS carbon emissions, conversations were based around the key recommendations to reverse this from the RPS' policies on sustainability," said RPS. The three key themes emphasised in all discussions were- the need to educate the public and change behaviours to avoid stockpiling medicines; How the clinical skills of prescribing pharmacists can be used for appropriate de-prescribing and switching patients to low carbon options; and importance of tackling waste. RPS Wales Director Elen Jones said: "It was fantastic to see how interested and engaged the politicians were around these important issues. By the end of our conversations, they all clearly understood and supported the importance of pharmacy leadership in this area, as well as the need for the link between climate change and medicines to be better understood by patients.

The Royal Pharmaceutical Society (RPS) has welcomed the appointment of Michael Matheson MSP as Cabinet Secretary for NHS Recovery, Health and Social Care in Scotland. Commenting on the announcement Laura Wilson, Director of RPS Scotland, said: "I would like to congratulate Michael Matheson on being appointed to this position. NHS recovery is vitally important, and pharmacy has a huge amount to offer this agenda. "Our current priorities include enabling pharmacists to take leadership of prescribing in all care settings, tackling health inequalities and advocating for change, implementing shared patient records between healthcare professionals to provide high-quality, person centred and safe patient care, improving pharmacists' wellbeing and tackling the climate emergency by encouraging sustainable and green prescribing across Scotland.

The Company Chemists' Association (CCA) has raised concern that pharmacies may face challenges in providing placements to pharmacy students graduating in 2025 due to shortages of designated prescribing practitioners (DPPs). From the academic year 2025/26, all pharmacy students will be required to complete 90 hours of training with designated prescribing practitioners prior to their registration. However, the CCA has raised doubts regarding the availability of these healthcare professionals to provide such training. The association said: "We are concerned that pharmacies will be unable to secure DPPs. This will result in a significant reduction in the number of Foundation Pharmacist placements available within the community pharmacy sector. Consequently, a significant number of graduates leaving university next year will, unfortunately, struggle to find employment in their chosen career." As per the CCA, they have repeatedly raised their concerns with NHS England and cautioned them about the potential consequences arising from the lack of DPPs.

Nearly 70 years ago the UK Government recognised the imbalance of power between commercial landlords and tenants and passed the Landlord and Tenant Act 1954 (the Act), giving most commercial tenants a right of security of tenure. What is security of tenure? The Act grants tenants of business premises (so this would include pharmacy tenants) the right when the fixed term of their lease has ended to remain in occupation of the premises and the right to apply for the grant of a new lease. The landlord can only object to the grant of the new lease of the premises to the tenant, and therefore regain possession of the property on certain grounds set out in the Act. The parties to a lease can contract outside the provisions of the Act and where this is the case, a tenant would not have security of tenure. Most landlords will insist on no security of tenure where a lease is granted for a short term. As pharmacy leases have tended to be granted for longer terms (usually between 10 and 15 years) pharmacy tenants often have security of tenure. The Act sets out strict procedures which need to be followed to both contract outside the provisions of security of tenure and also to exercise the security of tenure rights granted by the Act. Pharmacists should take legal advice before agreeing to a pharmacy lease being excluded from the Act, and also at the end of their lease term whether or not they have security of tenure. If the lease is contracted outside of the Act, advice should be sought on agreeing new lease terms, if the pharmacist wishes to remain, as there will be no right to do so beyond the end of the lease term. If the lease is protected by the security of tenure provisions of the Act, advice should still be sought, as the Act prescribes a formal notice procedure that both the landlord and tenant must adhere to, before a new lease can be granted.

The International Pharmaceutical Federation (FIP) has issued a new policy statement which encourages a "life-course" approach to vaccination by pharmacists. In the statement, published on September 27, FIP backed expansion of vaccine schedules and strategies so that patients of all age groups could be vaccinated throughout their entire lifespan, from infancy to old age. A life-course approach in public health and healthcare focuses on an individual's health and well-being, including vaccination, administered throughout their entire lifespan, from infancy to old age. FIP urged governments and policymakers to eliminate regulatory barriers, enabling pharmacists to prescribe and administer all relevant vaccines throughout the life-course. Additionally, FIP recommended that policymakers develop remuneration models for pharmacies to deliver sustainable life-course vaccination services within the private and public sectors.

The International Pharmaceutical Federation (FIP) launched a report on pharmacy-led common ailment schemes. The data was collected from 24 countries, including case studies from nine countries. It highlighted the growing demand for care models for ageing populations and the increase in chronic non-communicable diseases. Pharmacists had been managing the stress, including prescribing authority and provision of medicinal treatments. Paul Sinclair AM, Global President of FIP, said, "I believe this report is both a foundation and a catalyst - a foundation on which FIP and our member organizations could base initial strategies and a catalyst to drive us to seek even more diverse and comprehensive insights in the future.

The General Pharmaceutical Council (GPhC) has alerted pharmacists, pharmacy technicians, and pharmacy owners via email regarding new emergency legislation governing the prescribing and supply of puberty-suppressing hormones, commonly known as 'puberty blockers', for children and young people under 18 in England, Wales, and Scotland. The regulations apply to gonadotropin-releasing hormone (GnRH) analogues, used to suppress puberty as part of treating gender incongruence or gender dysphoria in individuals under 18. Effective from 3 June 2024, new private prescriptions for GnRH analogues from prescribers in the European Economic Area (EEA) or Switzerland who are not UK registered are banned from being dispensed in Great Britain for patients under 18. The emergency ban on these medicines will remain in effect until September 3, 2024, the Department of Health and Social Care (DHSC) announced on 29 May, stating that the action has been taken to address risks to "patient safety."

Online pharmacies have to operate from bricks & mortar premises that are registered with the General Pharmaceutical Council, but recent cases show that, in reality, the practices of online pharmacies are often very different to other pharmacies, and the regulation of online pharmacies is also different - and evolving as issues arise. For a start, the General Pharmaceutical Council (GPhC) is only one of the regulators taking an interest in online pharmacy services. Other regulators include the Medicines and Healthcare products Regulatory Agency (MHRA) which enforces the advertising and promotion of medicines, and the Care Quality Commission (CQC) which regulates prescribing services. The different regulation of online pharmacies is attributable to the higher risk to patients and the public from medicines bought online. These risks often arise from a combination of patients who do not tell the truth in order to obtain medicines and the nature of a transaction in which a pharmacist does not see patients face-to-face. "The GPhC has strong enforcement powers that it uses when it considers its premises standards have not complied with." However, there are also things that go wrong because pharmacists have simply failed to act professionally or take sufficient care, as well as cases where things have gone wrong through misfortune.

England's chief pharmaceutical officer (CPhO) David Webb has promised his "wholehearted support" for the community pharmacy sector at the board meeting of the National Pharmacy Association (NPA) on 28 June in St Albans. After hearing the CPhO at the meeting, NPA chair, Andrew Lane, later declared: "David is someone we can do business with." Webb thus listed his priorities as head of profession: integration of independent prescribing as part of pharmacy practice by 2026; promotion of inclusive pharmacy practice for all pharmacy professionals; assurance of post-registration practice; developing the role of pharmacy technicians; support for Integrated Care Systems and Primary Care Network pharmacy teams (including community pharmacy); medicines optimisation; and strengthening of professional leadership for community pharmacy. He also reported that NHS England had recently increased its team of regional pharmacy integration leads from seven to 14, creating seven new senior posts. Webb told NPA board members: "I want sincerely to thank community pharmacy teams for everything they are doing and to say that you have my wholehearted support. I believe in the importance of community pharmacy and will listen and engage as I've already demonstrated.

A Company Chemists' Association (CCA) analysis has shown that 'Pharmacy First' service in England could free up 30m+ GP appointments each year. It has urged the Government and NHS to be even 'bolder in their ambition and go further and faster'. The recent 'Delivery plan for recovering access to primary care' announced a 'Pharmacy First' service for England, mirroring similar approaches in Scotland and Wales. The association has estimated that with the added capability to supply non-prescription medicines and prescribe additional prescription-only medicines, an ambitious 'Pharmacy First' service could free up 30m+ GP appointments annually. Harnessing community pharmacies to deliver care for minor health conditions will effectively create 11,000 urgent care centres in England.

The Health Committee's new report has reminded the government of a much-needed pharmacy workforce plan to support recruitment, training, and retention of staff. The report makes a number of recommendations to optimise workloads across primary care, reduce pressure on general practice and hospitals, and support the integrated care systems. It also recognises the potential of pharmacist independent prescribers to support patient care, backed by appropriate supervision, training, and opportunities for professional development. RPS England gave evidence to MPs on the Committee at a public hearing in May, highlighting key issues to support the pharmacy workforce. RPS director for England, Ravi Sharma, said: "Today's report underlines the urgent need for the Government to set out a comprehensive workforce plan for health and care. "It rightly recognises that boosting recruitment and retention, supporting staff wellbeing, fostering inclusion and diversity, and investing in education and training will be crucial to the future of the NHS.

The Department of Health and Social Care (DHSC) has issued Serious Shortage Protocols (SSPs) on three HRT medicines to limit dispensing supply to three months. To ensure women across the UK will be able to more reliably access HRT products SSPs has been issued on the supply of Oestrogel, Ovestin cream and Premique Low Dose. DHSC stated, "Women who have a prescription for more than three months but are only able to access three months' supply will not have to pay an additional prescription charge." "This means women will not incur any additional costs. Imposing a three month limit will mean more women are able to access the medication they want. Any woman who is worried about access to HRT or is unable to access HRT should speak to her GP." Recently, Vaccine Taskforce Director General Madelaine McTernan has been appointed to spearhead a new HRT Supply Taskforce, applying lessons learned from the successful procurement seen during the Covid vaccination programme to identify ways to support the HRT supply chain ensuring it can meet both short and long term demand. The move will save time for patients as well as pharmacists and prescribers who are working tirelessly to tackle the covid backlog.

Women in the UK will be able to purchase Gina 10 mg vaginal tablets without prescription from September from their local pharmacies, announced the Medicines and Healthcare products Regulatory Agency (MHRA). The Hormone Replacement Therapy (HRT) product, Gina 10 microgram vaginal tablets (containing estradiol) are used for the treatment of vaginal symptoms such as dryness, soreness, itching, burning and uncomfortable sex caused by oestrogen deficiency in postmenopausal women aged 50 years and above who have not had a period for at least one year. The decision to reclassify these vaginal tablets follows a safety review by the MHRA, independent advice from the Commission on Human Medicines (CHM), and a public consultation. The UK regulator sought views from patients, pharmacists, prescribers and a wide range of stakeholders including the Royal College of Obstetricians & Gynaecologists, the Faculty of Sexual & Reproductive Healthcare, the British Pharmacopoeia Commission and the British Menopause Society.

There has been extensive national media coverage today (August 11) on how medicine shortages have forced patients to visit multiple pharmacies to get their prescriptions filled or return to their GP to be prescribed alternative drugs. These media reports have been based on a survey involving more than 1,500 pharmacists in the UK, in which over a half of those polled said that their patients' health had been put at risk in the last six months. In response to a query from Pharmacy Business, the Department of Health and Social Care (DHSC) said it monitors the medicines supply chain closely to prevent any shortages and acts swiftly when any issue arises. A DHSC spokesperson told Pharmacy Business: "We take patient safety extremely seriously and we routinely share information about medicine supply issues directly with the NHS so they can put plans in place to reduce the risk of any shortage impacting patients, including offering alternative medication.

Over the last few years, we've seen the aftermath of Covid-19, with the demand for consumer health products being unprecedented and unpredictable, placing pressure on supply chains and labour market. In turn, the industry has experienced acute shortages across the healthcare sector, placing huge pressure on pharmacists, doctors, nurses, and other healthcare professionals. Europe has an estimated shortage of around 50,000 public-sector doctors[1], which is set to increase in the coming years. While this shortage stems from several complex problems, there is a hidden force that could play a key part in helping to alleviate this burden. That force is the potential of self-care. Encouragingly, last month the UK government recognised the unique role that self-care can play through the introduction of its Delivery plan for recovering access to primary care. Through this, it has pledged to empower patients to manage their own health through several commitments, including improving accessibility to online tools and reclassifying medicines to make formerly prescribed options available over the counter.